Azurity Pharmaceuticals has announced that lisdexamfetamine dimesylate (Arynta) oral solution will be available mid-2026 for treating attention-deficit/hyperactivity disorder (ADHD) in adults and pediatric patients aged 6 years, and older.1 The medication received US Food and Drug Administration approval in June 2025 for ADHD, as well as for moderate to severe binge eating disorder in adults.2 This new formulation aims to provide a more flexible treatment option for individuals who prefer or require a liquid medication.
“Azurity Pharmaceuticals is proud to offer Arynta as an option for patients who need or prefer an oral liquid and are seeking flexibility in their treatment options,” said Ronald Scarboro, chief executive officer of Azurity Pharmaceuticals.
Lisdexamfetamine, the active ingredient in Arynta, demonstrated statistically significant efficacy in phase 3 clinical trials for managing the core symptoms of hyperactive-impulsive and inattention in both pediatric and adult populations with ADHD.1 As a prodrug of amphetamine, Arynta is designed to provide sustained symptom control, delivering effects for up to 13 hours in children and up to 14 hours in adults.1 The safety and tolerability profile of lisdexamfetamine is generally consistent with other stimulant medications used to treat ADHD.
The development of Arynta addresses a significant need for alternative formulations of ADHD medication. Research indicates that a substantial number of patients, particularly children and adolescents, experience difficulty swallowing pills or capsules.4 Approximately 70% of children and 30% of adolescents either refuse or struggle with swallowing solid oral medications.4 This can lead to inconsistent medication adherence and potentially suboptimal treatment outcomes.
Certain patient populations face even greater challenges with oral medication. For example, around 40% of children with autism also have ADHD, and many children with autism experience food texture hypersensitivity, making it difficult to take medication in capsule or sprinkle form.5-8 The availability of a liquid formulation like Arynta offers a potential solution for these individuals, improving their ability to consistently receive their prescribed treatment.
The prodrug nature of Arynta – meaning it’s converted into an active drug within the body – may also offer advantages regarding abuse potential compared to immediate-release formulations of amphetamine.3 A study comparing lisdexamfetamine and dextroamphetamine exposures reported to U.S. Poison centers suggested a potentially lower risk of abuse with lisdexamfetamine.3 However, as with all stimulant medications, careful monitoring and adherence to prescribing guidelines are essential.
The introduction of Arynta represents an expansion of treatment options for ADHD, catering to a broader range of patient needs and preferences. The oral solution is designed to be stored at room temperature, between 68°F to 77°F (20°C to 25°C), simplifying storage requirements.1
While Arynta offers a promising new option, it’s important for patients and healthcare providers to discuss the potential benefits and risks of any medication, considering individual circumstances and medical history. The full Prescribing Information, including a Boxed Warning, is available at www.arynta/full-prescribing-information.
References
1. Azurity Pharmaceuticals announces ARYNTA™ (lisdexamfetamine dimesylate) oral solution, CII. News release. February 10, 2026. Accessed February 11, 2026. https://www.globenewswire.com/news-release/2026/02/10/3235646/0/en/Azurity-Pharmaceuticals-Announces-ARYNTA-lisdexamfetamine-dimesylate-Oral-Solution-CII.html
2. FDA approves Arynta. Drugs.com. June 16, 2025. Accessed February 11, 2026. https://www.drugs.com/newdrugs/fda-approves-arynta-lisdexamfetamine-oral-solution-adhd-binge-eating-disorder-6564.html
3. Kaland ME, Klein-Schwartz W. Comparison of lisdexamfetamine and dextroamphetamine exposures reported to U.S. Poison centers. Clin Toxicol (Phila). 2015. 53(5):477-485.
4. Polaha J, Dalton WT 3rd, Lancaster BM. Parental report of medication acceptance among youth: implications for everyday practice. South Med J. 2008;101(11):1106-1112.
5. Houghton R, Ong RC, Bolognani F. Psychiatric comorbidities and use of psychotropic medications in people with autism spectrum disorder in the United States. Autism Res. 2017;10(12):2037-2047.
6. ADHD in Youth With ASD: Parents’ Medication Guide. American Academy of Child and Adolescent Psychiatry. 2023. Accessed February 11, 2026. https://www.aacap.org/App_Themes/AACAP/docs/resource_centers/resources/med_guides/ADHDwithASD_Web.pdf
7. Cermak SA, Curtin C, Bandini LG. Food selectivity and sensory sensitivity in children with autism spectrum disorders. J Am Diet Assoc. 2010;110(2):238-246.
8. Cutler AJ, Mattingly GW. Beyond the pill: new medication delivery options for ADHD. CNS Spectr. 2017;22(6):463-474.
